What is the recommended administration method of Denosumab?

Denosumab is a monoclonal antibody that is primarily used in the management of conditions related to bone health, such as osteoporosis and certain types of bone metastases. The recommended administration method is through subcutaneous injection. This route is preferred because it allows the medication to be absorbed effectively into the systemic circulation, providing the necessary therapeutic effects on bone metabolism.

Subcutaneous administration is advantageous as it is relatively easy to perform, can often be done by patients at home, and avoids the complications associated with intravenous infusions, such as the need for venous access and a longer administration time. Moreover, Denosumab has specific pharmacokinetic properties that are optimized when administered subcutaneously, contributing to its efficacy in reducing bone resorption and increasing bone density.

The other methods, such as oral tablets or topical applications, are not suitable for Denosumab due to the molecule's large size and the need for it to be delivered directly into the system without being degraded in the gastrointestinal tract or absorbed through the skin. Intravenous infusion is also not standard practice for this medication, further emphasizing that subcutaneous injection is the most effective and recommended method of administration.